Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 31, 2024
Finance

Axonis advancing KCC2 program with $115M series A

BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Apr 9, 2024
Discovery & Translation

AACR brings new modalities, new targets to glioblastoma

BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
BioCentury | Jul 30, 2022
Data Byte

Assessing an expanse of ALS targets 

Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Mar 4, 2022
Distillery Therapeutics

Inhibiting TXNDC5 signaling to reduce atherosclerosis

BioCentury | May 1, 2020
Distillery Therapeutics

Thioredoxin reducing enzyme inhibitors for solid tumors

BioCentury | May 20, 2019
Distillery Therapeutics

Analog of pleuromutilin identified for multiple cancers

BioCentury | Nov 9, 2018
Distillery Techniques

Chemistry; drug platforms

BioCentury | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

Why ECM remodeling pathways could be the source of new cancer metabolism targets
BioCentury | Mar 7, 2018
Distillery Therapeutics

Neurology

BioCentury | Feb 28, 2017
Distillery Therapeutics

Cardiovascular

Items per page:
1 - 10 of 69